Liu, H., et al. Harnessing natural saponins: Advancements in mitochondrial dysfunction and therapeutic applications.
Liu, H., et al. Harnessing natural saponins: Advancements in mitochondrial dysfunction and therapeutic applications. Phytomedicine, 2025 Mar, 138:156383. PMID: 39848019 T...
Read More
Pal, P.B. and Lyer, S.S. Transient pain and long-term gain: adjuvant dose directs immune memory.
Pal, P.B. and Lyer, S.S. Transient pain and long-term gain: adjuvant dose directs immune memory. J Clin Invest, 2025 Apr 15, 135(8):e190524. PMID: 40231461 The paper disc...
Read More
Ramezani-Rad, P., et al. The saponin monophosphoryl lipid A nanoparticle adjuvant induces dose-dependent HIV vaccine responses in nonhuman primates.
Ramezani-Rad, P., et al. The saponin monophosphoryl lipid A nanoparticle adjuvant induces dose-dependent HIV vaccine responses in nonhuman primates. J Clin Invest, 2025 M...
Read More
Leroux-Roels, I., et al. Safety and Immunogenicity of an Adjuvanted Clostridioides difficile Vaccine Candidate in Healthy Adults: A Randomized Placebo-Controlled Phase 1 Study.
Leroux-Roels, I., et al. Safety and Immunogenicity of an Adjuvanted Clostridioides difficile Vaccine Candidate in Healthy Adults: A Randomized Placebo-Controlled Phase 1 ...
Read More
Ison, M.G., et al. Efficacy, safety, and immunogenicity of the AS01E-adjuvanted respiratory syncytial virus prefusion F protein vaccine (RSVPreF3 OA) in older adults over three respiratory syncytial virus seasons (AReSVi-006): a multicentre, randomised, observer-blinded, placebo-controlled, phase 3 trial.
Ison, M.G., et al. Efficacy, safety, and immunogenicity of the AS01E-adjuvanted respiratory syncytial virus prefusion F protein vaccine (RSVPreF3 OA) in older adults over...
Read More
Venkatraman, N., et al. Evaluation of a novel malaria anti-sporozoite vaccine candidate, R21 in Matrix-M adjuvant, in the UK and Burkina Faso: two phase 1, first-in-human trials.
Venkatraman, N., et al. Evaluation of a novel malaria anti-sporozoite vaccine candidate, R21 in Matrix-M adjuvant, in the UK and Burkina Faso: two phase 1, first-in-human...
Read More
Haine, V., et al. Safety of RTS,S/AS01E malaria vaccine up to 1 year after the third dose in Ghana, Kenya, and Malawi (EPI-MAL-003): a phase 4 cohort event monitoring study.
Haine, V., et al. Safety of RTS,S/AS01E malaria vaccine up to 1 year after the third dose in Ghana, Kenya, and Malawi (EPI-MAL-003): a phase 4 cohort event monitoring stu...
Read More
Venkatraman, N., et al. R21 in Matrix-M adjuvant in UK malaria-naive adult men and non-pregnant women aged 18-45 years: an open-label, partially blinded, phase 1-2a controlled human malaria infection study.
The study evaluates the efficacy and safety of the R21 malaria vaccine candidate (Jenner Institute, University of Oxford) formulated with the Matrix-M adjuvant (Novavax) ...
Read More